EUVIMEDEUVIMED entdecken
Open Access

Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-β Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis

Yunzhou Dong, Beibei Wang, Mulong Du, Bo Zhu, Kui Cui iD, Kathryn Li, Ke Yuan, Douglas B Cowan iD, Sudarshan Bhattacharjee, Scott Wong, Jinjun Shi iD, Da-Zhi Wang und 4 weitere

Circulation · 21.02.2023 · 147 (8) · 669-685

DOI: 10.1161/circulationaha.122.063075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 21.02.2023. Verfasst von Yunzhou Dong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Biology Program (Y.D., B.W., B.Z., K. Cui, K.L., D.B.C., S.B., S.W., J.B., H.C.), Boston Children's Hospital, MA. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Atherosclerosis. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epsin endocytic adaptor proteins are implicated in the progression of atherosclerosis; however, the underlying molecular mechanisms have not yet been fully defined. In this study, we determined how epsins enhance endothelial-to-mesenchymal transition (EndoMT) in atherosclerosis and assessed the efficacy of a therapeutic peptide in a preclinical model of this disease.

Methods

Using single-cell RNA sequencing combined with molecular, cellular, and biochemical analyses, we investigated the role of epsins in stimulating EndoMT using knockout in Apoe −/− and lineage tracing/proprotein convertase subtilisin/kexin type 9 serine protease mutant viral-induced atherosclerotic mouse models. The therapeutic efficacy of a synthetic peptide targeting atherosclerotic plaques was then assessed in Apoe −/− mice.

Results

Single-cell RNA sequencing and lineage tracing revealed that epsins 1 and 2 promote EndoMT and that the loss of endothelial epsins inhibits EndoMT marker expression and transforming growth factor-β signaling in vitro and in atherosclerotic mice, which is associated with smaller lesions in the Apoe −/− mouse model. Mechanistically, the loss of endothelial cell epsins results in increased fibroblast growth factor receptor-1 expression, which inhibits transforming growth factor-β signaling and EndoMT. Epsins directly bind ubiquitinated fibroblast growth factor receptor-1 through their ubiquitin-interacting motif, which results in endocytosis and degradation of this receptor complex. Consequently, administration of a synthetic ubiquitin-interacting motif–containing peptide atheroma ubiquitin-interacting motif peptide inhibitor significantly attenuates EndoMT and progression of atherosclerosis.

Conclusions

We conclude that epsins potentiate EndoMT during atherogenesis by increasing transforming growth factor-β signaling through fibroblast growth factor receptor-1 internalization and degradation. Inhibition of EndoMT by reducing epsin–fibroblast growth factor receptor-1 interaction with a therapeutic peptide may represent a novel treatment strategy for atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor betaAtherosclerosisMiceAnimalsFibroblast Growth FactorsApolipoproteins EReceptors, Fibroblast Growth FactorTransforming Growth FactorsUbiquitinsAdaptor Proteins, Vesicular Transport

Stichwörter der Autor:innen

EndoMTadaptor proteins, signal transducingatherosclerosisendocytosisepsinpeptidesreceptor, fibroblast growth factor, type 1single-cell gene expression analysistransforming growth factor betavascular diseases

Substanzen

Transforming Growth Factor betaFibroblast Growth FactorsApolipoproteins EReceptors, Fibroblast Growth FactorTransforming Growth FactorsUbiquitinsepsinAdaptor Proteins, Vesicular Transport

Autor:innen und Institutionen

  • Vascular Biology Program (Y.D., B.W., B.Z., K. Cui, K.L., D.B.C., S.B., S.W., J.B., H.C.), Boston Children's Hospital, MA.
  • Departments of Surgery (Y.D., B.W., B.Z., K. Cui, D.B.C., S.B., J.B., H.C.), Harvard Medical School, Boston, MA.
  • Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA (M.D.).
  • Department of Medicine (K.Y.), Boston Children's Hospital, MA.
  • Pediatrics (K.Y., K. Chen), Harvard Medical School, Boston, MA.
  • Department of Anesthesia (J.S.), Harvard Medical School, Boston, MA.

ORCID-Profile: Kui Cui, Douglas B Cowan, Jinjun Shi, Kaifu Chen, Joyce Bischoff, MacRae F Linton, Hong Chen

Förderung

  • NIGMS NIH HHS
  • NHLBI NIH HHS
  • BLRD VA

Zitieren

APA

Dong, Y., Wang, B., Du, M., Zhu, B., Cui, K., Li, K., Yuan, K., Cowan, D. B., Bhattacharjee, S., Wong, S., Shi, J., Wang, D. Z., Chen, K., Bischoff, J., Linton, M. F., & Chen, H. (2023). Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-β Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis. Circulation, 147(8), 669-685. https://doi.org/10.1161/circulationaha.122.063075

Vancouver

Dong Y, Wang B, Du M, Zhu B, Cui K, Li K, et al. Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-β Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis. Circulation. 2023;147(8):669-685. doi:10.1161/circulationaha.122.063075

BibTeX
@article{Dong2023,
  author = {Dong, Yunzhou and Wang, Beibei and Du, Mulong and Zhu, Bo and Cui, Kui and Li, Kathryn and Yuan, Ke and Cowan, Douglas B and Bhattacharjee, Sudarshan and Wong, Scott and Shi, Jinjun and Wang, Da-Zhi and Chen, Kaifu and Bischoff, Joyce and Linton, MacRae F and Chen, Hong},
  title = {Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-β Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis},
  journal = {Circulation},
  year = {2023},
  volume = {147},
  number = {8},
  pages = {669--685},
  doi = {10.1161/circulationaha.122.063075}
}
Kostenlos starten →